| 摘要 |
PURPOSE: Provided is a method for the treatment of polyposis which comprises treating a subject suffering from polyposis with an H+, K+-ATPase inhibitor and, optionally, a glucocorticoid. Also provided is a pharmaceutical formulation for simultaneous, separate or sequential administration in the treatment of Widal's Syndrome and in the treatment of asthma. CONSTITUTION: Provided is a method for the treatment of nasal polyps which method comprises treating a subject suffering from the said condition with a K+ -ATPase inhibitor. Al the use of an H+, K+-ATPase inhibitor in the manufacture of a medicament for the treatment of nasal polyps. H+, K+-ATPase inhibitors are a known class of pharmaceutical agents generally used in therapy for the treatment of gastric acid related diseases. Examples of H+, K+-ATPase inhibitors are for instance compounds known under the generic names omeprazole, lansoprazole, pantoprazole, rabeprazole and leminoprazole. Some of these compounds are for instance disclosed in EP-A1-0005129, EP-A1-174726, EP-A1-166287 and GB 2163747. These pharmaceutical substances are generally known to be useful for inhibiting gastric acid secretion in mammals and man by controlling gastric acid secretion at the final step of the acid secretory pathway. Thus, in a more general sense, they may be used for prevention and treatment of gastric-acid related diseases in mammals and man, including e.g. reflux oesophagitis, gastritis, duodenitis, gastric ulcers and duodenal ulcers. It has now surprisingly been found that H, K+-ATPase inhibitors are useful in the treatment of nasal polyps, particularly where known treatments have failed. The H, K+-ATPase inhibitors preferably used in the invention are compounds of the general formula 1
|
